Viking Therapeutics, Inc. Investing Cash Flow
Viking Therapeutics, Inc. (VKTX) reported Investing Cash Flow of $163.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-29
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $109.43M, a 157.45% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $54.19M, a 14.32% decline year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $75.61M, a 1048.42% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $160.03M, a 517.83% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $341.39M.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$553.37M.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$179.09M, a 427.08% decline from fiscal 2022.
- Viking Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $54.75M, a 44.24% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $109.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $163.62M 10-Q · filed 2026-07-29 | $239.23M derived: sum of 3 quarters · filed 2026-07-29 | $399.26M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $54.19M 10-Q · filed 2026-04-30 | $129.80M derived: sum of 2 quarters · filed 2026-04-30 | $289.83M derived: sum of 3 quarters · filed 2026-04-30 | $332.33M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $75.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $235.64M derived: sum of 2 quarters · filed 2026-02-11 | $278.14M derived: sum of 3 quarters · filed 2026-07-29 | $341.39M 10-K · filed 2026-02-11 |
| 2025-09-30 | $160.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $202.53M derived: sum of 2 quarters · filed 2026-07-29 | $265.78M 10-Q · filed 2025-10-23 | $272.36M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $42.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $105.75M 10-Q · filed 2026-07-29 | $112.33M derived: sum of 3 quarters · filed 2026-07-29 | $138.24M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $63.24M 10-Q · filed 2026-04-30 | $69.83M derived: sum of 2 quarters · filed 2026-04-30 | $95.73M derived: sum of 3 quarters · filed 2026-04-30 | -$30.33M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $32.48M derived: sum of 2 quarters · filed 2026-02-11 | -$93.57M derived: sum of 3 quarters · filed 2026-02-11 | -$553.37M 10-K · filed 2026-02-11 |
| 2024-09-30 | $25.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$100.16M derived: sum of 2 quarters · filed 2025-10-23 | -$559.95M 10-Q · filed 2025-10-23 | -$524.22M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$126.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-23 | -$585.85M 10-Q · filed 2025-07-23 | -$550.12M derived: sum of 3 quarters · filed 2026-02-11 | -$562.65M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$459.79M 10-Q · filed 2025-04-24 | -$424.06M derived: sum of 2 quarters · filed 2026-02-11 | -$436.59M derived: sum of 3 quarters · filed 2026-02-11 | -$641.08M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $35.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $23.20M derived: sum of 2 quarters · filed 2026-02-11 | -$181.28M derived: sum of 3 quarters · filed 2026-02-11 | -$179.09M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$12.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-23 | -$217.02M derived: sum of 2 quarters · filed 2024-10-23 | -$214.82M 10-Q · filed 2024-10-23 | -$207.56M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$204.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | -$202.28M 10-Q · filed 2024-07-24 | -$195.03M derived: sum of 3 quarters · filed 2025-02-26 | -$168.13M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $2.20M 10-Q · filed 2024-04-25 | $9.46M derived: sum of 2 quarters · filed 2025-02-26 | $36.35M derived: sum of 3 quarters · filed 2025-02-26 | $55.33M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $34.15M derived: sum of 2 quarters · filed 2025-02-26 | $53.13M derived: sum of 3 quarters · filed 2025-02-26 | $54.75M 10-K · filed 2025-02-26 |
| 2022-09-30 | $26.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | $45.87M derived: sum of 2 quarters · filed 2023-10-25 | $47.49M 10-Q · filed 2023-10-25 | $74.90M derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | $18.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $20.60M 10-Q · filed 2023-07-26 | $48.01M derived: sum of 3 quarters · filed 2024-02-07 | $61.63M derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | $1.62M 10-Q · filed 2023-04-26 | $29.03M derived: sum of 2 quarters · filed 2024-02-07 | $42.65M derived: sum of 3 quarters · filed 2024-02-07 | $46.21M derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | $27.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $41.03M derived: sum of 2 quarters · filed 2024-02-07 | $44.59M derived: sum of 3 quarters · filed 2024-02-07 | $37.96M 10-K · filed 2024-02-07 |
| 2021-09-30 | $13.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $17.18M derived: sum of 2 quarters · filed 2022-10-26 | $10.55M 10-Q · filed 2022-10-26 | $40.82M derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | -$3.07M 10-Q · filed 2022-07-27 | $27.20M derived: sum of 3 quarters · filed 2022-07-27 | $17.57M derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | -$6.63M 10-Q · filed 2022-04-27 | $23.64M derived: sum of 2 quarters · filed 2022-04-27 | $14.01M derived: sum of 3 quarters · filed 2022-04-27 | $23.79M derived: sum of 4 quarters · filed 2022-04-27 |
| 2020-12-31 | $30.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $20.64M derived: sum of 2 quarters · filed 2022-02-09 | $30.41M derived: sum of 3 quarters · filed 2022-02-09 | $41.57M 10-K · filed 2022-02-09 |
| 2020-09-30 | -$9.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $146.00K derived: sum of 2 quarters · filed 2021-11-03 | $11.30M 10-Q · filed 2021-11-03 | $237.00K derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $9.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $20.93M 10-Q · filed 2021-07-28 | $9.87M derived: sum of 3 quarters · filed 2021-07-28 | $25.02M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $11.15M 10-Q · filed 2021-04-28 | $91.00K derived: sum of 2 quarters · filed 2021-04-28 | $15.24M derived: sum of 3 quarters · filed 2021-04-28 | $26.22M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | -$11.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $4.09M derived: sum of 2 quarters · filed 2021-02-17 | $15.07M derived: sum of 3 quarters · filed 2021-02-17 | $7.46M 10-K · filed 2021-02-17 |
| 2019-09-30 | $15.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $26.13M derived: sum of 2 quarters · filed 2020-10-28 | $18.52M 10-Q · filed 2020-10-28 | -$123.87M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $10.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $3.37M 10-Q · filed 2020-07-29 | -$139.02M derived: sum of 3 quarters · filed 2020-07-29 | -$166.11M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | -$7.61M 10-Q · filed 2020-04-30 | -$150.00M derived: sum of 2 quarters · filed 2020-04-30 | -$177.09M derived: sum of 3 quarters · filed 2020-04-30 | -$243.71M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | -$142.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$169.48M derived: sum of 2 quarters · filed 2020-02-26 | -$236.10M derived: sum of 3 quarters · filed 2020-02-26 | -$265.73M 10-K · filed 2020-02-26 |
| 2018-09-30 | -$27.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$93.71M derived: sum of 2 quarters · filed 2019-11-05 | -$123.34M 10-Q · filed 2019-11-05 | -$127.73M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | -$66.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$96.25M 10-Q · filed 2019-08-01 | -$100.65M derived: sum of 3 quarters · filed 2019-08-01 | -$99.26M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | -$29.63M 10-Q · filed 2019-05-02 | -$34.02M derived: sum of 2 quarters · filed 2019-05-02 | -$32.63M derived: sum of 3 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$3.00M derived: sum of 2 quarters · filed 2019-03-13 | -$1.73M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $2.67M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $1.27M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |